States and municipalities have brought over 200 lawsuits against opioid distributors and manufacturers in the United States, in response to the Opioid Epidemic. Using civil suits to solve this public health problem is not a proper function of the justice system. Opportunistic litigation diverts attention from the need for properly targeted public policy solutions.
Background
The Opioid litigation narrative in brief: Big Pharma overstated the benefits of opioids and downplayed their addiction properties, leading patients to overconsume their prescribed medication, becoming addicted. Complaints generally allege opioids are “over supplied” and “over prescribed,” ignoring the benefits of prescriptions opioids for patients in chronic pain, and assuming unproven causation.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
